



ACPE/JSPE2019

ISPE's 12th Asian Conference on Pharmacoepidemiology
11-13 October 2019 Kyoto, Japan



SATURDAY 12 OCTOBER 2019

08:00-08:20	Welcome ceremony		
Room:	Plenary Hall A		
Chair:	Frank May FISPE , ACPE12 Conference Co-Chair		
	Koji Kawakami , ACPE12 Conference Co-Chair and Local Host Committee Chair; Kyoto University, Japan Almut Winterstein FISPE , President, International Society for Pharmacoepidemiology; University of Florida, USA Kiyoshi Kubota FISPE , President, Japanese Society for Pharmacoepidemiology; NPO Drug Safety Research Unit Japan, Japan		
08:30-10:00	Contributed papers 1 – Substance abuse, opioids and pain	Symposium 1 - Variability and generalizability of claims-based algorithms in pharmacoepidemiologic research: Multinational perspectives	Symposium 2 – Data science and Pharmacoepidemiology in the next 10 Years
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Daisuke Koide , The University of Tokyo, Japan Mary-Beth Ritchey FISPE , RTI Health Solutions, USA	Soko Setoguchi FISPE , Rutgers University, USA Chieko Ishiguro , Pharmaceuticals and Medical Devices Agency (PMDA), Japan	Wei Zhou FISPE , Wei Zhou, Merck Research Laboratories, USA
08:30-08:45	The impact of substance abuse on healthcare resource utilization: Big data analytics using the clinical data in Hong Kong - #100 Yue Wei, The University of Hong Kong, China	The importance of validating outcomes when using claims data Brian Strom FISPE, Rutgers University, USA Operational challenges in the execution of validation studies of claims data in Japan: A review of inter-hospital variability of results from the Japan VALIDATE study Cynthia de Luise, Pfizer, USA	Data science and pharmacoepidemiology in RWE: What can we learn from each other and where must we differ Almut G. Winterstein FISPE, University of Florida, USA
08:45-09:00	Understanding patients with substance abuse and their healthcare pathway by using bigdata approach: Towards better management in Hong Kong - #101 Jia Xi Zhao, The University of Hong Kong, China		Overview in the use of RWE in the drug approval process and related challenges Nancy Santanello FISPE, Consultant, USA
09:00-09:15	The effects of more restrictive scheduling in 2018 on subsequent codeine use and harms in Australia - #102 Nicholas Buckley, NSW Poisons Information Centre; The University of Sydney, Australia		A perspective from Asia: RWE experience in Japan Koji Kawakami, Kyoto University, Japan

09:15-09:30	Transition to high-dose or strong opioids: A population-based study of people initiating opioids in Australia - #103 Jenni Ilomäki, Monash University, Australia	Validating administrative health data in Australia Benjamin Daniels, University of New South Wales, Australia	
09:30-09:45	A spatial-temporal analysis of adverse drug reactions due to opioid analgesic use in New South Wales - #104 Wei Du, Australian National University, Australia		
09:45-10:00	Trend in targeted therapy in patients with rheumatoid arthritis in Korea: A time-series analysis using nationwide health insurance data, 2010-2017 - #105 So-Hee Park, Sungkyunkwan University, South Korea		
10:00-10:30	Morning tea/coffee break with poster discussions		
Room:	Plenary Hall B		
	Presenters of original research within the following abstract themes will be attending their poster during the morning tea break for discussions with interested delegates. Pharmacoepidemiology and traditional medicines (poster boards 364 – 382) Pharmacogenomics research and drug safety (poster boards 383 – 388) Pharmaceutical policy and administration (poster boards 389 – 391) Other related fields (poster boards 426 – 449) Evidence-based medicine (poster boards 450 – 462) Prevention of medication errors and drug misuse/abuse (poster boards 463 – 466) Rational drug use (poster boards 467 – 474) Evidence-based pharmacy (poster boards 506 – 509) Rare disease and orphan medicines (poster boards 510 – 512) Post-marketing drug effectiveness and safety evaluation (poster boards 513 – 531)		
10:30-12:00	Contributed papers 2 – Patient management and palliative care	Symposium 3 - Challenges and strategies in the post market studies of Herbal and Traditional Medicine (HTM) products	Symposium 4 – Approaches to assess medication exposure and associated risks during pregnancy using Real-World Data
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Keisuke Matsubayashi , Kyoto University, Japan Nicole Pratt , University of South Australia	Soko Setoguchi FISPE , Rutgers University, USA	Kenneth Man , University College London, UK; University of Hong Kong, Hong Kong Keiko Asao , Amgen Astellas BioPharma K.K., Japan
10:30-10:45	Assessment of impact of different instructional interventions in training on inhalers amongst asthma and COPD patients - #106 Shilpa Palaksha, JSS College of Pharmacy, India	Real-world evidence initiative in China: An overview and its application to traditional Chinese medicine Xin Sun, West China Hospital, Sichuan University, China Safety regulation of herbal medicines of Korea Seong-Gyu Ko, Kyung Hee University College of Korean Medicine, Korea Current registration and review of Kampo products in Japan Takeshi Yoshioka, KOKANDO Co. Ltd., Japan	Use of RWD and pregnancy registries in the United States to assess medication exposure and associated risks during pregnancy Jeff Lange, Amgen Inc., USA Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: Population based cohort study Kenneth KC Man, University College London, UK; University of Hong Kong, Hong Kong
10:45-11:00	Impact of clinical pharmacist-led education on clinical and humanistic outcome of children with Thalassemia: A randomized control study - #107 Juny Sebastian, JSS College of Pharmacy, India		
11:00-11:15	Reducing medication burden in residential aged care: Simplification of Medications Prescribed to Long-term care Residents (SIMPLER) cluster randomised controlled trial - #108 Jenni Ilomaki and J Simon Bell, Monash University, Australia		

11:15-11:30	Efficacy of anti-emetic regimen in chemotherapy induced nausea vomiting and its impact on quality of life in pediatric cancer population - #109 Vanitha Rani Nagasubramanian, Sri Ramachandra Institute of Higher Education and Research, India	Pharmacovigilance practice of TCM drugs: Current status, challenges, and future directions Li Zhang, Dongfang Hospital, Beijing University of Chinese Medicine, China	Maternal-infant link using a Japanese administrative dataset Maki Ueyama, Creativ-Ceutical K.K., Japan
11:30-11:45	A Delphi study on the development of a risk proportionality framework for the selection of risk minimisation interventions in Asia - #110 Yola Moride FISPE, Université de Montreal, Canada; Rutgers, The State University of New Jersey, USA; YOLARX Consultants, Canada		Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from an administrative dataset Tomofumi Ishikawa, Tohoku University, Japan
11:45-12:00	The association between partner bereavement and incident psoriasis or atopic eczema: A matched cohort study - #111 Angel Wong, London School of Hygiene and Tropical Medicine, UK		
12:00-12:30	Lunch		
Room:	Plenary Hall B		
12:30-13:30	Plenary Presentation		
Room:	Plenary Hall A		
Co-Chairs:	Siyan Zhan, President, Chinese Society for Pharmacoepidemiology, Peking University, Beijing China Hisashi Urushihara, Keio University, Japan		
	Pharmacoepidemiology methods: Past, present, and advice about the future - #112 Brian Strom FISPE, Inaugural Chancellor of Rutgers Biomedical and Health Sciences, and Executive Vice President for Health Affairs at Rutgers University. USA		
13:30-15:00	Contributed papers 3 – Diabetes and other cardiovascular issues	Symposium 5 - Use of real-world evidence (RWE) in regulatory decision-making: Regulatory guidance and examples from Asia and the US	Contributed papers 4 – Paediatrics
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Chieko Ishiguro, Pharmaceuticals and Medical Devices Agency (PMDA), Japan Byung-Joo Park FISPE, Seoul National University College of Medicine, Korea	Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	Almut Winterstein FISPE, University of Florida, USA Ju-Young Shin, Sungkyunkwan University, South Korea
13:30-13:45	Antipsychotics use during pregnancy and the risk of gestational diabetes: A population-based cohort study - #113 Zixuan Wang, UCL School of Pharmacy, UK	Introduction and overview of the symposium Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	Association between relative age within school year and attention deficit hyperactivity disorder (ADHD), intellectual disability and depression - #119 Jeremy Brown, London School of Hygiene and Tropical Medicine, UK
13:45-14:00	Continuation of antipsychotic medication during pregnancy and the risk of gestational diabetes: A population-based cohort study - #114 Zixuan Wang, UCL School of Pharmacy, UK	Regulatory approach to Real-World Evidence in the United States Jeremy Rassen, Aetion, Inc., USA Regulation for Use of Real-World Evidence in post-marketing drug safety assessment in Japan	Efficacy of pidotimod in children: A systematic review - #120 Qiusha Yi, Sichuan University, China

14:00-14:15	Pharmacological treatment dynamics in people initially prescribed metformin or sulfonylurea for type 2 diabetes - #115 Stephen Wood, Monash University, Australia	Yusuke Okada, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	Antimicrobial resistant and prescribing pattern in children in Taiwan- TARPEC project - #121 Ching-Lan Cheng, National Cheng Kung University Hospital, Taiwan
14:15-14:30	Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors: A pharmacoepidemiological-pharmacodynamic assessment through an analysis of the VigiBase® - #116 Faizan Mazhar, Università di Milano, Italy	Use of Real-World Evidence to support drug development and regulatory decision in China Jasmanda Wu, Sanofi, USA and China	Patterns of methylphenidate and atomoxetine use among pediatric patients with attention-deficit/hyperactivity disorder in Taiwan from 2004 to 2017 - #122 Heng-Ching Liao, National Taiwan University, Taiwan
14:30-14:45	The use of insulin, diabetes status, and risk of progression after first episode of acute pancreatitis: A population-based cohort study - #117 Jaelim Cho, University of Auckland, New Zealand	Regulatory perspective and application of Real-World Evidence in Taiwan Chi-Chuan Wang, National Taiwan University, Taiwan	Association between methylphenidate and risk of seizure: A population-based self-controlled case series study - #123 Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong
14:45-15:00	Impact of multiple cardiovascular medication on mortality after an incidence of stroke: A 10-year cohort study - #118 Tiantian Ma, UCL School of Pharmacy, UK	Panel Discussion Darren Toh FISPE, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	Comparative effect of four antimalarial treatments on haematocrit in children in Southwest Nigeria - #124 Zacchaeus Olofin, University of Ibadan, Nigeria
15:00-15:45	Afternoon tea/coffee break with poster discussions		
Room:	Plenary Hall B		
	Presenters of original research within the following abstract themes will be attending their poster during the afternoon tea break for discussions with interested delegates. Pharmacoepidemiology and Pharmacovigilance research methods (poster boards 332 – 363) Drug utilization evaluation studies (poster boards 392 – 425) Drug safety risk monitoring, evaluation and prevention (poster boards 475 – 505)		
15:45-17:15	Contributed papers 5 - Cardiovascular and liver issues	Symposium 6 - Japan In Real Life: Data, evidence and an evolving regulatory framework for Pharmacovigilance	Contributed papers 6 - Dementia and older person issues
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Tsugumichi Sato , Tokyo University of Science, Japan Vincent Lo Re , University of Pennsylvania, USA	Robert Reynolds FISPE , GSK R&D, USA	Hisashi Urushihara , Keio University, Japan Takuhiro Yamaguchi , Tohoku University, Japan
15:45-16:00	Comparative risks of cardiovascular events associated with anti-VEGF therapy in real-life patients with macular diseases in Taiwan - #125 Wan-Ju Lee, National Cheng Kung University, Taiwan	Introduction: Evolving pharmacovigilance regulations in Japan Robert Reynolds FISPE, GSK R&D, USA	Does statin use change in relation to the initiation of dementia medicine? Analysis of the Australian pharmacy claims data - #131 Leonie Picton, Monash University, Australia
16:00-16:15	Acute kidney injury associated with non-steroidal anti-inflammatory drugs and concomitant use of renin-angiotensin system inhibitors and diuretics: A case-crossover study - #126 Shao-En Weng, National Taiwan University, Taiwan	Real world data-driven evidence: Experience in outcomes research and safety assessment in Japan Masato Takeuchi, Kyoto University, Japan	Benzodiazepines, Z-hypnotics and risk of dementia: Special considerations of half-lives and concomitant use - #132 Shih Tsung Huang, National Taiwan University, Taiwan
16:15-16:30	Prevalence of aspirin non-responsiveness and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention - #127 Sheetal Chauhan, Manipal Academy of Higher Education, India	PMDA's experience of MID-NET utilization for post-marketing drug safety assessment Takashi Ando, Pharmaceuticals and Medical Devices Agency, Japan	Trazodone use and risk of dementia: A population-based cohort study - #133 Wallis C.Y. Lau, University College London, UK

16:30-16:45	Statin-associated dose-dependent reductions in non-alcoholic fatty liver diseases among people without any liver disease - #128 Sunyoung Cho, Yonsei University, South Korea	How pharmaceutical companies are using RWD for safety assessment Cynthia de Luise, Pfizer, USA Applying lessons from the US/EU experience to use RWD and produce valid RWE in Japan Soko Setoguchi FISPE, Rutgers University, USA	The association between cholinesterase inhibitors and subsequent cardiovascular events among older patients with Alzheimer's disease in Taiwan - #134 Chung-Hsuen Wu, Taipei Medical University, Taiwan
16:45-17:00	Effect of early initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral haemorrhage - #129 Ming-Shyan Lin, Chang Gung Memorial Hospital, Taiwan		Acetylcholinesterase inhibitors, cardiosuppressive drugs, and adverse cardiac events in patients with dementia - #135 Izumi Sato, Rutgers University, USA; Kyoto University, Japan
17:00-17:15	Effect of synbiotic, probiotic and prebiotic on patients with non-alcoholic fatty liver disease: A systematic review and network meta-analysis - #130 Surasak Saokaew, University of Phayao, Thailand		Androgen deprivation therapy and the risk of dementia in Taiwan - #136 Chin Yao Shen, National Cheng Kung University, Taiwan
17:15-18:00 Introduction to Asian Pharmacoepidemiology (AsPEN) Symposium			
Room:	Plenary Hall A		
Co-Chairs	Nicole Pratt, University of South Australia, Australia Kiyoshi Kubota FISPE, NPO Drug Safety Research Unit Japan, Japan		
	Introduction to AsPEN Nam-Kyong Choi, Ewha Womans University, South Korea Examples of AsPEN collaborative work: Common Data Model in AsPEN Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan Example of collaborative projects among AsPEN collaborators Ju-Young Shin, Sungkyunkwan University, South Korea AsPEN achievements so far and the way forward Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong Panel discussion		
18:00	End of day 1		
19:00-22:00	Conference dinner		

SUNDAY 13 OCTOBER 2019

08:00-09:30	Contributed papers 7 - Statistical methods and signal detection	Symposium 7 - Real World Evidence to support new drug approval and label expansion	Symposium 8 – Post-market surveillance of medicines, vaccines and medical devices across the Asia-Pacific region: The next 10 Years
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Kotonari Aoki , Chugai Pharmaceuticals, Japan Shiro Tanaka , Kyoto University, Japan	K. Arnold Chan FISPE , National Taiwan University, Taiwan	Edward Chia-Cheng Lai , National Cheng Kung University, Taiwan Nam-Kyong Choi , Ewha Womans University, South Korea Kenneth Man , University College London, UK; University of Hong Kong, Hong Kong
08:00-08:15	Caveats on adjustment for additional confounders following insufficient propensity score balancing - #200 Tomohiro Shinozaki, Tokyo University of Science, Japan	Overview K. Arnold Chan FISPE, National Taiwan University, Taiwan	Introduction Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan
08:15-08:30	Multiple imputation for survival analysis with missing covariates using non-parametric estimation - #201 Yoshinori Takeuchi, The University of Tokyo, Japan	Use cases of Real World Evidence to support drug applications Jeff Lange, Amgen Inc., USA	Kenneth Man, University College London, UK; University of Hong Kong, Hong Kong
08:30-08:45	A comparison of structural nested accelerated failure-time models and structural nested mean models for survival outcomes - #202 Shiro Tanaka, Kyoto University, Japan	Utilization of Real World Data to support new drug approval: PMDA perspective Yuki Ando, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	AsPEN-Vaccines SIG: Establishing an active vaccine safety monitoring system Nam-Kyong Choi, Ewha Womans University, South Korea
08:45-09:00	Comparison of dynamic treatment regime using inverse probability weighting for dialysis patients - #203 Yukari Uemura, National Center for Global Health and Medicine, Japan	How to assess Real World Data quality Wei Zhou FISPE, Merck Research Laboratories, USA	AsPEN-Biologics SIG: Post-marketing safety evaluation of immune check point inhibitor with the use of historical comparator Ju-Young Shin, Sungkyunkwan University, South Korea
09:00-09:15	Analysis of spontaneous adverse event reports derived from real-world EMR data for prospective pharmacovigilance - #204 Hyunah Shin, Konyang University Hospital, South Korea	Methodology consideration for using RWE for new drug application and label expansion K. Arnold Chan FISPE, National Taiwan University, Taiwan	AsPEN-Medical device SIG: Identifying predictors of medical device complications using medication prescribing patterns Nicole Pratt, University of South Australia, Australia
09:15-09:30	Evaluation of Tree-based Scan Statistic for drug safety signal detection in a Chinese healthcare database: A Plasmode simulation - #205 Hailong Li, Sichuan University, China	Discussion	Panel discussion Session moderators, speakers and Gianluca Trifirò, University of Messina, Italy; Mary-Beth Ritchey FISPE, RTI Health Solutions, USA

09:30-11:00	Morning tea/coffee break with poster discussions Presenters of all original research will be attending their poster during the morning tea break for discussions with interested delegates.		
Room:	Plenary Hall B		
09:45-11:00	Spotlight poster presentations A range of notable poster research reports have been pre-selected, and poster presenters will deliver a three minute description of their work followed by moderated audience discussions.		
	Policy, intervention and validation	Real world safety and effectiveness	Pharmacovigilance and drug safety
Room:	Conference Room 2	Conference Room 3	Craft Classroom
Moderator:	Nam-Kyong Choi , Ewha Womans University, South Korea	Mary-Beth Ritchey FISPE , RTI Health Solutions, USA	Nicole Pratt , University of South Australia, Australia
	Insights of healthcare work-force on establishing medication error reporting system in a tertiary care teaching hospital: A survey questionnaire - #300 Sri Harsha Chalasani, JSS College of Pharmacy, India	Effect of antipsychotics use on ischemic stroke in patients with atrial fibrillation and dementia - #311 Le Dai, National Taiwan University, Taiwan	Existence of notoriety bias in FDA Adverse Event Reporting System (FAERS) Database and its impact on signal strength - #322 Subeesh Kulangara Viswam, M.S. Ramaiah University of Applied Science, India
	Current status of re-examination of new drugs on regulatory safety actions in Korea - #301 Na-Young Jeong, Ewha Womans University, South Korea	The effectiveness of early use of long-acting injectable antipsychotics in patients with schizophrenia - #312 Su-Chen Fang, Taipei City Hospital, Taiwan	Aromatase inhibitors associated with osteonecrosis of Jaw: A disproportionality analysis in the USFDA Adverse Event Reporting System (FAERS) - #323 Subeesh Kulangara Viswam, M.S. Ramaiah University of Applied Science, India
	Trends and pattern of antibiotic prescriptions for adult outpatients with acute upper respiratory tract infections in Japan, 2008-2018 - #302 Lyu Ji, Kyoto University, Japan	The effectiveness of febuxostat in moderate to advanced chronic kidney disease patients with hyperuricemia or gout: A population-based study - #313 Chien Huei Huang, National Cheng Kung University Hospital, Taiwan	Population differences in incidence of allopurinol-related severe cutaneous adverse reactions in East Asians - #324 Kimie Sai, National Institute of Health Sciences, Japan
	Prevalence of potential drug-drug interactions in patients undergoing chemoradiotherapy and the impact of an expert team intervention - #303 Ashwin Kamath, Manipal Academy of Higher Education, India	Longitudinal impact of frailty and polypharmacy on risk of mortality in the elderly: A retrospective cohort study - #314 Shih Tsung Huang, National Taiwan University, Taiwan	Anomaly detection as a signal of adverse drug event from claims database: A case example of SGLT2 inhibitors - #325 Masato Takeuchi, Kyoto University, Japan
	Impact of drug safety communication on the use of hydroxyethyl starch in Taiwan: An interrupted time series study - #304 Chih-Wan Lin, National Taiwan University, Taiwan	Real-world effectiveness of switching from statin monotherapy to ezetimibe/simvastatin combination therapy - #315 Tsung Hsuan Lin, Chi Mei Medical Center, Taiwan	Association between diabetes treatment and urinary tract infections: An analysis using data from the JMDC claims database - #326 Akiko Tamon, Intage Healthcare Inc., Japan
	Association between pharmaceutical industry payments and prescribing a fixed-dose combination memantine extended released and donepezil: A cross-sectional study - #305 Zachary Marcum, University of Washington, USA	Effectiveness of statins for primary prevention of cardiovascular disease in an elderly Asian population - #316 Yu-Wen Lin, National Taiwan University, Taiwan	Proton-pump inhibitor use and the risk of progression to end-stage renal disease among chronic kidney disease patients in Taiwan - #327 Chih-Jung Tsai, and Chien Huei Huang, National Cheng-Kung University, Taiwan
	Validity assessment of self-reported medication use in a pharmacoepidemiology research (by comparing to medical and pharmacy insurance claims) - #306 Minako Matsumoto, Keio University School of Medicine, Japan	Treatment evolution and improved survival in multiple myeloma in Taiwan - #317 Yanfang Liu, Global Epidemiology, Janssen Research & Development, Singapore	Undela sheet: One platform for all quantitative signal detection analyses in Pharmacovigilance - #328 Krishna Undela, JSS College of Pharmacy, JSS Academy of Higher Education & Research, India

	Impact of pharmacist care in medication handling practices of paediatric dosage forms among caregivers - #307 Vasista Sharma, M.S Ramaiah University of Applied Sciences, India	Enoxaparin versus aspirin and aspirin combination in patients with spontaneous intracerebral haemorrhage - #318 Sreedharan Nair, Manipal College of Pharmaceutical Sciences, India	Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: A retrospective cohort study - #329 Wen Wang, West China Hospital, Sichuan University, China
	Validating the diagnosis of acute stroke in Japanese DPC data from Shiga Stroke and Heart Attack Registry - #308 Sachiko Tanaka, Shiga University of Medical Science, Japan	Duloxetine use and risk of coronary artery disease: Systematic review and meta-analysis - #319 Kyoungsoon Park, Seoul National University, South Korea	Safety analysis of pneumococcal vaccine in Korea using the KAERS database from 2005 to 2017 - #330 SeoungHun You, Chung-Ang University, South Korea
	Regimen and adverse drug reactions of anti-tuberculosis treatment and its associated direct medical costs – a patient cohort-based analysis - #309 Biao Xu, Fudan University, China	Combination of glycopeptide and β-lactam and risk of acute kidney injury - #320 Chi-Hao Shao, National Taiwan University, Taiwan	Predictors and preventability of adverse events following anaesthesia: An active surveillance in a tertiary care hospital - #331 Sri Harsha Chalasani, JSS College of Pharmacy, India
	Validation of renal failure diagnosis using laboratory data in the MDV database - #310 Naoyuki Yamamoto, CAC Croit Corporation, Japan	Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study - #321 Yu-Hsuan Shao, Taipei Medical University, Taiwan	
11:00-12:30	Contributed papers 8 – Adherence and prescription trends	Symposium 9 - Real World Evidence for decision making: Where we are in the Asia Pacific region?	Contributed papers 9 – Validation studies
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Takeo Nakayama , Kyoto University, Japan Edward Lai , National Cheng Kung University, Taiwan	Kiyoshi Kubota FISPE, NPO Drug Safety Research Unit Japan, Japan	Yoshinori Takeuchi , The University of Tokyo, Japan Nam-Kyong Choi , Ewha Womans University, South Korea
11:00-11:15	Medication non-adherence and its predictors among new antihypertensive initiators in Japanese working age patients - #206 Shiori Nishimura, The University of Tokyo; Keio University School of Medicine, Japan	Development and use of healthcare databases for safety and effectiveness assessment Solomon Iyasu, MSD, USA	Development and validation of ICD-10-based disease scoring system - #212 Young-Jin Ko, Seoul National University College of Medicine, South Korea
11:15-11:30	Adherence, persistence and clinical outcome between generic and brand-name statin users: Retrospective cohort study using Japanese claims database - #207 Jingwei Gao, Kyoto University, Japan	RWE generation using healthcare databases by study design in Korea Byung-Joo Park FISPE, Seoul National University College of Medicine, Korea	Development and validation of multi-view inappropriate medication use prescription detection model - #213 Zhuo Lin, Peking University, China
11:30-11:45	Participation in randomized controlled trials and subsequent medication adherence and quality of treatment in patients with cardiovascular diseases - #208 Natalia Vasyukova, National Medical Research Center for Preventive Medicine, Russian Federation	RWE generation from Industry perspective: How this can inform clinical practice and why Industry needs to collaborate Daniel J. Ruzicka, MSD KK, Japan	Impact of chronological changes in propensity to be exposed a comparison validity in health insurance claim database - #214 Daisuke Kato, Keio University; Astellas Pharma Inc., Japan
11:45-12:00	Trends and evaluation of online prescription fill among adults in the United States, 2009-2017 - #209 Lin-Ya Yang, Taipei Medical University, Taiwan	PMDA's initiative on real world data utilization for regulatory purposes Yoshiaki Uyama, Pharmaceuticals & Medical Devices Agency, Japan	Validity of claims-based definitions for ulcerative colitis in Japan: Methodology and pilot study results from the Validate-JUC study - #215 Sean Gardiner, Pfizer Japan Inc, Japan
12:00-12:15	Adverse drug reactions of Yunnan Baiyao capsule: A multi-center intensive monitoring study in China - #210 Bo Li, Beijing Hospital of Traditional Chinese Medicine, Beijing, China		Validity of claims-based definitions for rheumatoid arthritis, selected cancers and infectious diseases in Japan: Results from validate-J study - #216 Naonobu Sugiyama, Pfizer, Japan

12:15-12:30	An interrupted time series analysis for use of psychoactive medicines in Japan - #211 Tasuku Okui, Kyusyu University Hospital, Japan		Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia's Pharmaceutical Benefits Scheme (PBS) data - #217 Benjamin Daniels, University of New South Wales, Australia
12:30-14:00	Lunch with poster discussions		
Room:	Plenary Hall B		
14:00-15:30	Contributed papers 10 – Bone and biologics	Symposium 10 - Lessons learned and future challenges in international signal detection	Symposium 11 – Modern teaching of Pharmacoepidemiology in a 'Big Data' World
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Satomi Yoshida , Kyoto University, Japan Jung-Won Park , Yonsei University, Republic of Korea	Richard Hill , Therapeutic Goods Administration, Australia Andrew Bate , Pfizer, UK	Robert W. Platt , McGill University, Canada
14:00-14:15	Anti-osteoporosis treatment pattern after hip or vertebral fractures among postmenopausal women in China - #218 Hongxin Zhao, Shanghai Synyi Medical Technology Co., Ltd, China	Introduction Richard Hill, Therapeutic Goods Administration, Australia	Teaching the fundamentals of pharmacoepidemiology in a 'Big Data' world Kristian Fillion, McGill University, Canada
14:15-14:30	Changes of National Health Insurance reimbursement criteria on drug prescribing patterns and medical expenditures of osteoporotic fractures - #219 Chen-Yu Wang, National Taiwan University, Taiwan	Signal detection in distributed health data networks in the US: Lessons, barriers, and opportunities Jeffrey Brown, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	The use of platforms for teaching pharmacoepidemiology Seoyoung C. Kim, Harvard Medical School, USA
14:30-14:45	Osteoporotic fractures associated with the use of rivaroxaban vs warfarin or dabigatran among patients with atrial fibrillation - #220 Wallis Lau, UCL School of Pharmacy, UK; The University of Hong Kong, Hong Kong	Signal detection for drug safety using Japanese Real World Data Chieko Ishiguro, Pharmaceuticals and Medical Devices Agency (PMDA), Japan	What pharmacoepidemiologists need to learn about machine learning Nicole Pratt, University of South Australia, Australia
14:45-15:00	A database study of clinical features and treatment patterns with biologics in patients with Crohn's disease in Japan - #221 Yanfang Liu, Janssen Research & Development, Singapore	Multiple data stream surveillance for Real World Evidence generation Andrew Bate, Pfizer, UK	The use of distributed research network for teaching pharmacoepidemiology Rae Woong Park, Ajou University, South Korea
15:00-15:15	Prevalence, safety and long-term retention rates of biologics in Hong Kong from 2001 to 2015 - #222 Mengqin Ge, Li Ka Shing Faculty of Medicine, Hong Kong		
15:15-15:30	Safety regarding infectious events of biosimilars compared to other drugs in rheumatoid arthritis: A systematic review and network meta-analyses - #223 Yao Chen, Peking University, China		Discussion
15:30-16:15	Afternoon tea/coffee break		
Room:	Plenary Hall B		

SUNDAY 13 OCTOBER 2019 continued

16:15-17:45	Contributed papers 11 – Cancer	Symposium 12 – Challenges and approaches to Pharmacoepidemiologic research in mental health	Symposium 13 – A new international collaboration to advance medication safety in people with neurodegenerative diseases: NeuroGEN
Room:	Conference Room	Plenary Hall A	Exhibition Hall A
Chair/ Moderator:	Azusa Hara , Keio University, Japan Yea-Huei Kao Yang FISPE , National Cheng Kung University, Taiwan	Soko Setoguchi FISPE , Rutgers University, USA	Ian Wong , The University of Hong Kong, Hong Kong Simon Bell , Monash University, Australia
16:15-16:30	Estimation of healthcare costs for multiple myeloma in Japan using a nationwide claims database - #224 Jia Guan, Kyoto University, Japan	Introduction Tobias Gerhard FISPE, Public Health Rutgers University, USA	Global collaboration to advance medication safety: Challenges, opportunities and where to from now? Ian Wong, The University of Hong Kong, Hong Kong Simon Bell, Monash University, Australia Case study from the UK: Transforming a single country study into an international study Wallis Lau, University College London, UK Case study from Australia: Investigating medication use and safety using only medication data Jenni Ilomaki, Monash University, Australia Development of distributed network structures for NeuroGEN studies Edward Lai, National Cheng Kung University, Taiwan
16:30-16:45	Use of Phosphodiesterase 5 inhibitors reduces risk of colorectal cancer in men with benign colorectal neoplasms - #225 Jianguang Ji, Lund University, Sweden	Mortality risk of antipsychotic augmentation for depression Tobias Gerhard FISPE, Public Health Rutgers University, USA	
16:45-17:00	Compare effectiveness of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan - #226 Yan-Lin Wang and Kai-Cheng Chang, Linkou Chang Gung Memorial Hospital, Taiwan	Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD) Ju-Young Shin, Sungkyunkwan University, South Korea	
17:00-17:15	Comparative efficacy and safety of angiogenesis inhibitors in the treatment of non-small cell lung cancer: Systematic review and network meta-analysis - #227 Kirati Kengkla and Surasak Saokaew, University of Phayao, Thailand	Comparative mortality associated with ziprasidone and olanzapine (ZODIAC) Brian Strom FISPE, Rutgers University, USA	
17:15-17:30	Comparing effectiveness of first-line tyrosine kinase inhibitors in advanced lung adenocarcinoma patients with EGFR mutation using real-world data - #228 Yi-Hsin Yang, National Institute of Cancer Research, Taiwan	Questions and discussion moderated by Soko Setoguchi FISPE, Rutgers University, USA	
17:30-17:45			
17:45-18:00	Closing, farewell and Award ceremony		
Room:	Plenary Hall A		
Chair:	Shiro Tanaka , Local Host Committee, Kyoto University, Japan		
	Frank May FISPE , ACPE12 Conference Co-Chair James Vrac , Executive Secretary, International Society for Pharmacoepidemiology; Presentation of 'Rising Star' Award: Ms Samanta Lalic , Centre for Medicine Use and Safety, Monash University, Parkville, Australia, and Pharmacy Department, Austin Health, Melbourne, Australia 'Transition to high-dose or strong opioids: A population-based study of people initiating opioids in Australia' - #103 Announcement of the Seoul ACPE13 meeting – 15-17 October 2020 Jung-Won Park and Nam-Kyong Choi		
18:00	End of day 2		